Somewhat Positive Media Coverage Unlikely to Impact EnteroMedics (ETRM) Share Price
News articles about EnteroMedics (NASDAQ:ETRM) have been trending somewhat positive this week, according to Alpha One Sentiment. Alpha One, a division of Accern, identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. EnteroMedics earned a daily sentiment score of 0.25 on Alpha One’s scale. Alpha One also assigned news articles about the medical device company an impact score of 31 out of 100, meaning that recent media coverage is unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Alpha One Sentiment’s scoring:
- NetworkNewsBreaks – EnteroMedics, Inc. (NASDAQ: ETRM) Shares Surge on First vBloc® Neurometabolic Therapy Implant (4-traders.com)
- Stock Update: Focusing on Shares of EnteroMedics Inc. (NASDAQ:ETRM) – Business Daily (oxfordbusinessdaily.com)
- EnteroMedics Announces First vBloc® Neurometabolic Therapy … – PR Newswire (press release) (prnewswire.com)
- Technical analysis of EnteroMedics Inc. (NASDAQ:ETRM)’s metrics – FinancialsTrend (financialstrend.com)
- EnteroMedics (ETRM) Stock: Gaining On New Facility’s First Patient Treatment (cnafinance.com)
Shares of EnteroMedics (NASDAQ:ETRM) traded down 2.35% during mid-day trading on Friday, reaching $4.57. The company’s stock had a trading volume of 735,914 shares. EnteroMedics has a one year low of $1.75 and a one year high of $56.00. The firm’s market cap is $31.41 million. The firm’s 50 day moving average is $4.95 and its 200 day moving average is $4.60.
EnteroMedics (NASDAQ:ETRM) last released its quarterly earnings data on Tuesday, May 16th. The medical device company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.64. The company had revenue of $0.04 million for the quarter. EnteroMedics had a negative return on equity of 1,361.34% and a negative net margin of 3,236.52%. On average, equities analysts anticipate that EnteroMedics will post ($3.67) earnings per share for the current fiscal year.
Separately, Ladenburg Thalmann Financial Services assumed coverage on EnteroMedics in a research note on Wednesday, May 3rd. They issued a “buy” rating and a $11.00 price target on the stock.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/05/20/enteromedics-etrm-getting-somewhat-favorable-media-coverage-study-finds-updated.html.
EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Stock Ratings for EnteroMedics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc and related stocks with our FREE daily email newsletter.